Thesis
Immunoinformatic Analysis of PRDX6, E6, & E7 to Formulate Multi-Epitope Peptide-Based Vaccine for Cervical Cancer
Cervical cancer is included in the fourth list of most common cancer among women worldwide
and the second top cancer among women in Indonesia. However, the available method to fight this
cancer is only prevention, such as screening and prophylactic vaccination. As most cases arise from
women who have not gotten HPV vaccination, developing a therapeutic vaccine is essential. Most of
the cases are caused by the infection of HPV-16 & HPV-18. Thus, this research aims to develop multiepitopes
based-vaccine cancer vaccines for the Indonesian population, from oncogenic E6 & E7
proteins of HPV-16 & HPV-18. In addition, the PRDX6 protein that is expressed and overexpressed in
cervical cancer was also analysed. The netCTLpan and netMHCIIpan tools were used to detect the
peptide that can bind to the MHC class I and MHC class II, respectively. Continuously, predicted MHC
class I epitopes that were immunogenic and MHC class II epitopes with a good score of IFN-γ were in
vaccine constructs. The new vaccine construct (VC) was analysed for its antigenicity, allergenicity,
physicochemical characteristic, homology with other human peptides, and in silico simulation of the
immune response. Lastly, molecular docking was conducted for the vaccine construct and TLR4 to see
the conformational interactions. As a result, nine CTL epitopes and five HTL epitopes were chosen to
be included in the VC. Moreover, the analysis shows that the VC is non-allergen, immunogenic, can
induce IFN-γ, stable, non-homologous to other human peptides, and able to induce the activity of
immune response.
No other version available